HRAS Mutant Tumor
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations (NCT02383927) | Kura Oncology, Inc. | 2015-05-13 |
Track HRAS Mutant Tumor automatically
Every clearance here is in the API, with alerts when new ones post.